Uracyl spirooxetane nucleosides
US10301347B2 · kind B2 · utility
1Cited by
157References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 2018 |
| Grant date | May 28, 2019 |
| Priority date | — |
| Expiry date | Dec 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.